About SN BioScience
SN BioScience is a company based in Seoul (South Korea) founded in 2017. It operates as a HealthTech. SN BioScience has raised $4.44 million across 1 funding round from investors including OCI. SN BioScience offers products and services including SNB-101 and Drug Delivery System. SN BioScience operates in a competitive market with competitors including TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Shattuck Labs, among others.
- Headquarter Seoul, South Korea
- SectorsTechnologyHealthcare
- Email••••••••
- Phone•••• ••••
- Website snbioscience.com
- Social LinkedIn YouTube
- Legal Name Sn Bioscience Co., Ltd.
- Total Equity Funding$4.44M (USD)
in 1 rounds
- Latest Funding Round$4.44M (USD), Series A
Jan 2019
- Investors
Products & Services of SN BioScience
SN BioScience offers a comprehensive portfolio of products and services, including SNB-101 and Drug Delivery System.
Investigational drug developed for small cell lung cancer.
Innovative system designed for effective drug delivery solutions.
Apps and channels of SN BioScience
its YouTube channel SN Bioscience has 10 subscribers.
Funding Insights of SN BioScience
SN BioScience has successfully raised a total of $4.44M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.44 million completed in January 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.44M
- Total Rounds 1
- Last Round Series A — $4.44M
- First Round $4.44M
(Jan 2019)
- Investors Count 1
All 1 funding rounds of SN BioScience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2019 | $4.44M | Series A | – | – |
1 investors in total: 1 institutional.
Investors in SN BioScience
SN BioScience has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include OCI.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Petrochemicals, carbon materials, and basic chemicals are supplied by OCI. | 1959 | oci.co.kr | Seoul, South Korea |
Investor details for SN BioScience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of SN BioScience
2 dated milestones of SN BioScience across 2 years, from founding to its latest funding, stage changes and deals.
- Founded SN BioScience is founded.
- Funding First funding round of $4.4M.
Competitors of SN BioScience
SN BioScience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Shattuck Labs, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. | |
| lyell.com | 2018 | San Francisco, United States | $493M | 224 | CAR-T and TIL immunotherapies for solid tumors are developed. | |
| hummingbirdbioscience.com | 2015 | Singapore | $150M | – | Antibody drugs for cancer treatment are developed. | |
| gigagen.com | 2011 | San Francisco, United States | $36.13M | 36 | T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | |
| shattucklabs.com | 2016 | Austin, United States | $165.4M | 89 | An immunotherapy platform for oncology and other diseases is developed. | |
| candeltx.com | 1999 | United States | $110.3M | 76 | Viral immunotherapies are developed for cancer treatment. | |
| sirnaomics.com | 2007 | Gaithersburg, United States | $267M | 88 | RNA-based therapeutics for cancer and fibrosis are developed. | |
| boundlessbio.com | 2018 | San Diego, United States | $251.99M | 29 | Therapeutics for cancer are developed by targeting ecDNA. | |
| jacobiopharma.com | 2015 | Beijing, China | $55M | – | Small molecule therapeutics for cancer treatment are developed. | |
| liquidia.com | 2004 | United States | $75.3M | 63 | Engineered particles & films for life and material sciences applications |
Detailed competitors of SN BioScience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SN BioScience
The website of SN BioScience (snbioscience.com) receives about 3.6K visits a month.
- Monthly visits3.6K
▼ 28.9% vs previous month
Latest news on Sn Bioscience
Complete news archive for SN BioScience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to SN BioScience
10 companies that operate in the same segment as SN BioScience (Nanotechnology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Developer of technologies for analysis of genetic variation and function | 1993 | San Diego, California, United States | USD 28 M | USD 1.44 M | 29 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Technology tools and systems for molecular scale are developed. | 1959 | Abingdon, Oxfordshire, United Kingdom | – | USD 648.1 M | – | |
Aerogel-based thermal insulation solutions are provided for energy conservation. | 2001 | United States | USD 198.35 M | USD 271.1 M | 554 | |
Nanotech-based electrode materials for supercapacitors are provided. | 2009 | Boston, Massachusetts, United States | USD 163.32 M | – | 66 | |
Instrument systems and software for single-molecule real-time sequencing are developed. | 2004 | Menlo Park, California, United States | USD 395 M | USD 160 M | 575 | |
Nanotech-based wound care products are developed and provided. | 2010 | Madison, Wisconsin, United States | USD 22.7 M | – | 35 | |
Conductive nanocoatings are delivered via atomic layer deposition technology. | 2013 | Boulder, Colorado, United States | USD 202.75 M | – | – | |
RNA therapeutics for hematology and cardiovascular diseases are developed. | 1999 | London, England, United Kingdom | – | USD 559 K | 116 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about SN BioScience
SN BioScience was founded in 2017 and raised its 1st funding round 2 years after it was founded.
SN BioScience is headquartered in Seoul, South Korea.
SN BioScience is a funded company, having raised a total of $4.44M across 1 funding round to date. The company's 1st funding round was a Series A of $4.44M, raised on Jan 2019.
SN BioScience is engaged in research and development of innovative nano-medicine solutions for treating various diseases. The company specializes in drug delivery systems and is dedicated to ensuring patient safety while providing access to investigational therapies. Key focus areas include treatments for small cell lung cancer, with products like SNB-101 advancing through clinical trials. Their work spans across biotechnology and healthcare sectors, aiming to improve therapeutic outcomes through advanced technology.
SN BioScience's top competitors include Hummingbird Bioscience, Lyell Immunopharma and GigaGen.
SN BioScience offers SNB-101 and Drug Delivery System.
SN BioScience has 1 investor. Key investors include OCI.
SN BioScience operates through Sn Bioscience Co., Ltd..